ESH prespective

Client Success Stories Global Primary Market Research

Specialty Pharma

Foster Rosenblatt

Business Situation Business development team asked Foster Rosenblatt to conduct commercial diligence into the sales value of an oncology Phase III compound in the US & EU to support negotiations for potential licensing/acquisition

Approach & Methodology

- Company's complete commercial diligence required in-depth exploration of physician insights into utility of the product in the new indication, and comparison of product's profile compared to existing products in the market
- As such, FR led the design, execution and analysis of appropriate primary market research (PMR) studies, utilizing both in-person and tele-depth interviews

 The study was fielded with 50 total interviews, of which 26 were from the US, 10 from France, 7 from Italy and 8 from Germany

Deliverables & Business Outcomes

 Market overview and forecast assumptions based on market research (PMR and secondary research) Deep market insights that described potential future utilization of the product to support licensing or acquisition negotiations

Executive Summary Treatment Patterns

Foster Rosenblatt

HCPs reported that 61% of XXX patients are started on XXX with no intention to switch to XXX & ~20% of XXX patients will be switched to XXX at some point




 Treatment initiation with XXX has increased compared to XXX as physicians have gained experience and familiarity with the therapy – in Wave 1, 51% of XXX patients were started on XXX with the intention of staying on XXX continuously and in Wave 2, it was 56% of PI patients

Executive Summary

HCP Segmentation

Foster Rosenblatt

Only 32% (X out of X target list HCPs) maintained their originally-assigned segment & off-target list respondents were most likely to be XXXXX



 There was a decrease in XXXX & increase in XXXXX when HCPs were retyped, suggesting that XXXXX is continuing to be used, but overall XXXXX use is less than 70%

 These shifts in segmentation are consistent with what was observed in XXXXX where 30% of respondents maintained their segments (these observations were not reported in Wave 2); in addition, Wave 1 off-list respondents also were skewed towards XXXXX



© COPYRIGHT 2022. ALL RIGHTS RESERVED. PRIVILEGED & CONFIDENTIAL